

**GAVRETO
(pralsetinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic non-small cell lung cancer (NSCLC)
 - a. 18 years of age or older
 - b. *RET* fusion-positive detected by an FDA approved test
2. Advanced or metastatic thyroid cancer
 - a. 12 years of age or older
 - b. *RET* fusion-positive and patient requires systemic therapy
 - c. Radioactive iodine-refractory (if radioactive iodine is appropriate)

AND ALL of the following:

- a. Prescriber agrees to monitor AST, ALT, and blood pressure
- b. Females of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Gavreto and for 2 weeks after the final dose
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Gavreto and for 1 week after the final dose

Prior - Approval Limits

Quantity 360 capsules per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic non-small cell lung cancer (NSCLC)
 - a. 18 years of age or older
2. Advanced or metastatic thyroid cancer



**BlueCross
BlueShield**

Federal Employee Program.

**GAVRETO
(pralsetinib)**

- a. 12 years of age or older

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor AST, ALT, and blood pressure
- c. Females of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Gavreto and for 2 weeks after the final dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Gavreto and for 1 week after the final dose

Prior - Approval *Renewal* Limits

Same as above